Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer

[1]  Ying Cheng,et al.  Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial , 2023, Signal Transduction and Targeted Therapy.

[2]  Shi Yan,et al.  Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. , 2023, Lung cancer.

[3]  I. Wistuba,et al.  Impact of Region-of-Interest Size on Immune Profiling Using Multiplex Immunofluorescence Tyramide Signal Amplification for Paraffin-Embedded Tumor Tissues , 2022, Pathobiology.

[4]  Lei Cao,et al.  Pathological complete response to neoadjuvant ceritinib of a crizotinib‐resistant, stage IIIB non‐small cell lung cancer with ALK rearrangement: A case report , 2021, Thoracic cancer.

[5]  Tao Yu,et al.  Profiling Tumor Immune Microenvironment of Non-Small Cell Lung Cancer Using Multiplex Immunofluorescence , 2021, bioRxiv.

[6]  L. Boni,et al.  Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial. , 2021, Clinical lung cancer.

[7]  N. Ajami,et al.  Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial , 2021, Nature Medicine.

[8]  Y. Liao,et al.  Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer , 2021, Oncoimmunology.

[9]  Erin L. Schenk,et al.  Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing , 2020, Cell.

[10]  S. Lim,et al.  Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer , 2020, Journal for ImmunoTherapy of Cancer.

[11]  Yi-long Wu,et al.  Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  Prasad Adusumilli,et al.  IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  Yi-long Wu,et al.  Rapid Postoperative Relapse in ALK-Positive Locally Advanced NSCLC Patient with Complete Pathological Response to Neoadjuvant Crizotinib. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  M. Tsuboi,et al.  P1.18-04 Neoadjuvant Ceritinib for Locally Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: SAKULA Trial , 2019, Journal of Thoracic Oncology.

[15]  Yi-long Wu,et al.  Neoadjuvant Crizotinib in Resectable Locally Advanced Non–Small Cell Lung Cancer with ALK Rearrangement , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  O. Dizdar,et al.  Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability , 2019, Cancer Chemotherapy and Pharmacology.

[17]  P. Wen,et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.

[18]  A. Broeks,et al.  Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma , 2018, Nature Medicine.

[19]  A. Sharpe,et al.  The diverse functions of the PD1 inhibitory pathway , 2017, Nature Reviews Immunology.

[20]  Yi-long Wu,et al.  Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status , 2015, Journal of Hematology & Oncology.

[21]  Sarah Burdett,et al.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data , 2014, The Lancet.

[22]  Jeffrey W. Clark,et al.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. , 2011, The Lancet. Oncology.

[23]  L. Stewart,et al.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data , 2010, The Lancet.

[24]  T. Ley,et al.  Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. , 2007, Immunity.